GlassScriptPhysician profile
Jolene Melius
NPI 1215651278
$7,386.35
in general payments reported to CMS, 2019-2025
36 companies · $2,587 in 2025
The $2,587 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $74.03 · 2023: $2,515 · 2024: $2,210 · 2025: $2,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,312.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,082.22 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $958.57 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $669.61 | 2022-2025 | |
| Pfizer INC. | $594.52 | 2023-2025 | |
| Lilly USA, LLC | $569.80 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $532.74 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $395.82 | 2023-2025 | Linzess |
| Astellas Pharma US INC | $269.47 | 2023-2025 | Veozah |
| Novo Nordisk INC | $242.47 | 2022-2025 | Wegovy, Ozempic, Saxenda |
| Exact Sciences Corporation | $216.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ardelyx, INC. | $197.70 | 2023-2025 | Ibsrela |
| Lundbeck LLC | $178.28 | 2023-2025 | Vyepti, Rexulti |
| Aimmune Therapeutics, INC. | $173.54 | 2024-2025 | Zenpep |
| Glaxosmithkline, LLC. | $126.82 | 2023-2024 | Bexsero, Shingrix, Rotarix |
| Axsome Therapeutics, INC. | $118.67 | 2023-2025 | Symbravo, Auvelity |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $101.26 | 2023-2025 | Slynd |
| Nestle Healthcare Nutrition INC. | $100.59 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.53 | 2023-2024 | Jardiance |
| Amgen INC. | $73.89 | 2024-2025 | Otezla, Repatha, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.61 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.10 | 2023 | Xifaxan, Relistor |
| Dexcom, INC. | $65.68 | 2024-2025 | Dexcom G6 Transmitter |
| Neurelis, INC. | $61.85 | 2023 | Valtoco |
| Mayne Pharma Commercial LLC | $50.45 | 2023 | |
| Xeris Pharmaceuticals, INC. | $48.70 | 2024-2025 | Gvoke Hypopen |
| Cranial Technologies, INC | $48.03 | 2024-2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $47.63 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $37.86 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $33.85 | 2023 | Livalo |
| Viiv Healthcare Company | $32.41 | 2023-2024 | Dovato, Apretude |
| Vanda Pharmaceuticals INC. | $23.85 | 2024 | Fanapt |
| Pulmonx Corporation | $22.66 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| E.R. Squibb & Sons, L.L.C. | $20.00 | 2024 | Camzyos |
| Paratek Pharmaceuticals, INC. | $18.74 | 2024 | Nuzyra |
| Corcept Therapeutics | $17.82 | 2023 | Korlym |
| Sanofi Pasteur INC. | $17.66 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jolene Melius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.